IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Sarkissyan, Suren ^a   Sarkissyan, Marianna ^a   Wu, Yanyuan ^a,b   Cardenas, Jessica ^a   Koeffler, H Phillip ^b,c   Vadgama, Jaydutt V ^a,b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH PROTEIN 61; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; TRANSCRIPTION FACTOR FKHR; UVOMORULIN; CADHERIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER CELL LINE; BT474 CANCER CELL LINE; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL MIGRATION ASSAY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MCF 7 CELL LINE; MDA MB23 CANCER CELL LINE; MTT ASSAY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SKBR3 CANCER CELL LINE; TUMOR GROWTH; UPREGULATION; WILD TYPE; 3T3 CELL LINE; ANIMAL; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; BREAST NEOPLASMS; CADHERINS; CELL MOVEMENT; CELL PROLIFERATION; CYSTEINE-RICH PROTEIN 61; FORKHEAD TRANSCRIPTION FACTORS; INSULIN-LIKE GROWTH FACTOR I; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MICE;

EID: 84904872977     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103534     Document Type: Article

References (38)

1. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593.
2. Brigstock DR (1999) The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 20: 189-206.
3. Holbourn KP, Acharya KR, Perbal B (2008) The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33: 461-473.
4. O'Kelly J, Chung A, Lemp N, Chumakova K, Yin D, et al. (2008) Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol 33: 59-67.
5. (1993) Proceedings of the 4th International Symposium on Insulin, IGFs, and their Receptors. Woods Hole, Massachusetts, April 20-23, 1993. Adv Exp Med Biol 343: 1-417.
6. LeRoith D, Baserga R, Helman L, Roberts CT Jr (1995) Insulin-like growth factors and cancer. Ann Intern Med 122: 54-59.
7. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34.
8. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, Sciacca L (1998) Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 47: 255-267. (Pubitemid 28059821)
9. Karey KP, Sirbasku DA (1988) Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res 48: 4083-4092.
10. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, et al. (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84: 1418-1423. (Pubitemid 19272227)
11. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57: 330-340.
12. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, et al. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396. (Pubitemid 28209997)
13. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, et al. (2006) IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13: 593-605. (Pubitemid 43886679)
14. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, et al. (2007) Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 16: 763-768. (Pubitemid 46650579)
15. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, et al. (1990) Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82: 1693-1697.
16. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12: 159-169.
17. Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, et al. (2008) Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 10: R3.
18. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV (2010) FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res 70: 5475-5485.
19. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, et al. (2001) Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 276: 14187-14194.
20. Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, et al. (2012) Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res 2: 104-115.
21. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, et al. (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55: 3551-3557.
22. Tolia M, Zygogianni A, Kouvaris JR, Meristoudis C, Margari N, et al. (2014) The key role of bisphosphonates in the supportive care of cancer patients. Anticancer Res 34: 23-37.
23. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP (2001) Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61: 8917-8923. (Pubitemid 34013909)
24. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R (2002) Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21: 8178-8185. (Pubitemid 35454421)
25. Sampath D, Winneker RC, Zhang Z (2001) Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer. Endocrinology 142: 2540-2548. (Pubitemid 32473110)
26. Menendez JA, Mehmi I, Griggs DW, Lupu R (2003) The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer 10: 141-152. (Pubitemid 36758643)
27. Fowke JH, Matthews CE, Yu H, Cai Q, Cohen S, et al. (2010) Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3. Endocr Relat Cancer 17: 51-60.
28. Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE (2005) Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev 14: 2147-2153. (Pubitemid 41603260)
29. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, et al. (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97: 439-448.
30. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, et al. (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2: 84-89.
31. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83.
32. De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110.
33. Chai J, Norng M, Modak C, Reavis KM, Mouazzen W, et al. (2010) CCN1 induces a reversible epithelial-mesenchymal transition in gastric epithelial cells. Lab Invest 90: 1140-1151.
34. Lai D, Ho KC, Hao Y, Yang X (2011) Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 71: 2728-2738.
35. Lin J, Huo R, Wang L, Zhou Z, Sun Y, et al. (2012) A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother 61: 677-687.
36. Jim Leu SJ, Sung JS, Huang ML, Chen MY, Tsai TW (2013) A novel anti- CCN1 monoclonal antibody suppresses Rac-dependent cytoskeletal reorganization and migratory activities in breast cancer cells. Biochem Biophys Res Commun 434: 885-891.
37. Leask A, Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119: 4803-4810. (Pubitemid 46017793)
38. Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, et al. (2005) A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 24: 761-779. (Pubitemid 40216085)